Rational topical treatment of uncomplicated rhinosinusitis as a basis for successful recovery

The article is devoted to the treatment of one of the most common diseases - the treatment of rhinosinusitis. According to statistics only 2% of the sinusitis in population are bacterial. At the same time administration of systemic antibiotic therapy reaches 95.5%. The problem of rational prescription of antibacterial drugs, including management of the rhinosinusitis, is very acute, especially considering the constant increase in the number of antibiotic-resistant microorganisms. Currently, the level of patients with prolonged post-viral rhinosinusitis after COVID-19 has increased. Most have a history of one or more courses of systemic antibiotics and, often, without indications. In article are listed indications for systemic and local antibacterial therapy in adults and children, based on national and European clinical guidelines. The data on complications during the use of systemic antibacterial drugs are presented. Authors give information about the advantages of the local use of antibiotics: the absence of general toxic complications, the creation of an optimal concentration directly in the focus of inflammation. The advantages of combining solutions of neomycin and polymyxin B for topical use, such as a pronounced bactericidal effect against gram-positive and gram-negative bacteria (Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa), causing the development of infectious processes in the upper respiratory tract, are separately noted. The author describes his own experience of using the original nasal spray Polydex with phenylephrine, containing a fixed combination of neomycin, polymyxin B, dexamethasone sodium metasulfobenzoate and phenylephrine, in the treatment of patients with post-viral rhinosinusitis. As a result of the collection of literature data, as well as based on their own experience, the authors concluded that the use of this nasal spray in outpatient practice will significantly improve the effectiveness of treatment and reduce the frequency of prescribing systemic antibiotics.

1. Fokkens W., Desrosiers M., Harvey R., Hopkins C., Mullol J., Philpott C. et al. EPOS2020: Development Strategy and Goals for the Latest European Position Paper on Rhinosinusitis. Rhinology. 2019;57(3):162– 168. doi: 10.4193/Rhin17.253.

2. Wald E.R., Guerra N., Byers C. Upper Respiratory Tract Infections in Young Children: Duration of and Frequency of Complications. Pediatrics. 1991;87(2):129–133.

3. Ryazantsev S.V. The Principles of Etiopathogenetic Treatment of Acute Sinusitis. Meditsinskiy sovet = Medical Council. 2014;(15):13– 17. (In Russ.) doi: 10.21518/2079-701X-2014-15-13-17.

4. Lopatin A.S. (ed.). Acute Rhinosinusitis: Clinical Guidelines. Moscow: Rossiyskoye obshchestvo rinologov; 2017. 36 p. (In Russ.) Available at: http://rhinology.ru/wp-content/uploads/2017/09/Острыйриносинусит-21.09.pdf.

5. Bogomilskiy M.R., Chistyakova V.R. Pediatric otorhinolaryngology. Moscow: GEOTAR-MED; 2002. 432 p. (In Russ.) Avaliable at: http://www.booksshare.net/books/med/bogomolskiy-mr/2002/files/detskayaotorinolaringooliya2002.pdf.

6. Piskunov G.Z., Piskunov S.Z. Clinical rhinology. 3rd ed. Moscow: Meditsinskoe informatsionnoe agentstvo; 2017. 750 p. (In Russ.).

7. Piskunov G.Z., Piskunov S.Z. Diagnostics and Treatment of Inflammatory Processes of the Nasal Mucosa and Paranasal Sinuses. Voronezh: Voronezhskiy universitet; 1991. 182 p. (In Russ.).

8. Rachina S.A., Kozlov R.S., Tatochenko V.K., Zharkova L.P., Dudnikova E.V., Sakulina I.B. et al. Paediatricians Approach to Prescribing of Systemic Antimicrobials in Outpatient Children with Upper Respiratory Tract and ENT Infections: Data from Multicenter Survey. Klinicheskaya farmakologiya i terapiya = Clinical pharmacology and therapy. 2016;(2):20–27. (In Russ.) Available at: https://clinpharmjournal.ru/files/articles/praktika-lecheniya-ostryh-respiratornyhinfektsij-u-detej-v-ambulatorno-poliklinicheskih-uchrezhdeniyah-rfrezultaty-mnogotsentrovogo-farmakoepidemiologicheskogoissledovaniya.pdf.

9. Zharkova L.P., Stetsyuk O.U., Andreeva I.V., Egorova O.A. Current Trends in the Use of Protected Aminopenicillins for the Treatment of Respiratory Tract Infections in Outpatient Practice. Farmateka = Pharmateca. 2011:(4):8–16. (In Russ.) Available at: https://lib.medvestnik.ru/apps/lib/assets/uploads/pharmateca/PDF/8060.pdf.

10. Levy D.A., Nguyen S.A., Harvey R., Hopkins C., Schlosser R.J. Hospital Utilization for Orbital and Intracranial Complications of Pediatric Acute Rhinosinusitis. Int J Pediatr Otorhinolaryngol. 2020;128:109696. doi: 10.1016/j.ijporl.2019.109696.

11. Din-Lovinescu C., Mir G., Blanco C., Zhao K., Mazzoni T., Fried A. et al. Intracranial Complications of Pediatric Rhinosinusitis: Identifying Risk Factors and Interventions Affecting Length of Hospitalization. Int J Pediatr Otorhinolaryngol. 2020;131:109841. doi: 10.1016/j.ijporl.2019.109841.

12. Wang D.Y., Wardani R.S., Singh K., Thanaviratananich S., Vicente G., Xu G. et al. A Survey on the Management of Acute Rhinosinusitis among Asian Physicians. Rhinology. 2011;49(3):264–71. doi: 10.4193/Rhino10.169.

13. Brozek J.L., Akl E.A., Alonso-Coello P., Lang D., Jaeschke R., Williams J.W. et al. Grading Quality of Evidence and Strength of Recommendations in Clinical Practice Guidelines. Part 1 of 3. An Overview of the GRADE Approach and Grading Quality of Evidence about Interventions. Allergy. 2009;64(5):669–677. doi: 10.1111/j.1398-9995.2009.01973.x.

14. Jefferson T.O., Tyrrell D. WITHDRAWN: Antivirals for the Common Cold. Cochrane Database Syst Rev. 2007;(3):CD002743. doi: 10.1002/14651858.CD002743.pub2.

15. Statsyuk O.U., Andreeva I.V., Kolosov A.V., Kozlov R.S. Antibiotic Safety and Tolerance in Outpatient Practice. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(1):67–84. (In Russ.) Available at: https://cmacjournal.ru/publication/2011/1/cmac-2011-t13-n1-p067/cmac-2011-t13-n1-p067.pdf.

16. Guo X., Nzerue C. How to Prevent, Recognize, and Treat Drug-Induced Nephrotoxicity. Cleve Clin J Med. 2002;69(4):289-297. doi: 10.3949/ccjm.69.4.289.

17. Abouesh A., Stone C., Hobbs W.R. Antimicrobial-Induced Mania (Antibiomania): A Review of Spontaneous Reports. J Clin Psychopharmacol. 2002;22(1):71–81. doi: 10.1097/00004714-200202000-00012.

18. Lipsky B.A., Baker C.A. Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agents. Clin Infect Dis. 1999;28(2):352–364. doi: 10.1086/515104.

19. Poluzzi E., Raschi E., Motola D., Moretti U., De Ponti F. Antimicrobials and the Risk of Torsades de Pointes: the Contribution from Data Mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303–314. doi: 10.2165/11531850-000000000-00000.

20. Elkov I.V., Khabarov A.A. Study of the Penetration of Morphocyclin into the Blood and the Mucous Membrane of the Maxillary Sinus. Zhurnal ushnykh, nosovykh i gorlovykh bolezney = Journal of Ear, Nasal and Throat Diseases. 1991;(3):9–11. (In Russ.).

21. Doht F., Hentschel J., Fischer N., Lehmann T., Markert UR, Böer K. Reduced Effect of Intravenous Antibiotic Treatment on Sinonasal Markers in Pulmonary Inflammation. Rhinology. 2015;53(3):249–259. doi: 10.4193/Rhin14.300.

22. Garashchenko T.I., Strachunskiy L.S. Antibiotic Therapy of ENT Diseases in Childhood. In: Bogomilskiy M.R., Chistyakova V.R. (eds.). Pediatric Otorhinolaryngology. Moscow: Meditsina; 2005. Vol. 2, pp. 275– 316 (In Russ.).

23. Balyasinskaya G.L., Bogomil’skiy M.R. The Use of Drugs “Polydexa with Phenylephrine” and “Isofra” in the Treatment of Inflammatory Diseases of the Nasal Cavity, Nasopharynx and Paranasal Sinuses in Children. Medi.ru. 2003. (In Russ.) Available at: https://medi.ru/info/6251/.

24. Garashchenko T.I., Tarasova G.D., Alferova M.V., Garashchenko M.V., Rogova E.S. Monotherapy of Post-Viral Rhinosinusitis in Childhood. Pediatriya = Pediatrics. 2019;98(2):127–132. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=369&section=5506.

25. Garaschenko T.I., Tarasova G.D., Alferova M.V., Garaschenko M.V., Rogova E.S. Modern Capabilities of Therapy of Post-Viral Rhinosinusitis in Children. Meditsinskiy sovet = Medical Council. 2018;(2):98– 104. (In Russ.) doi: 10.21518/2079-701X-2018-2-98-104.

26. Bezshapochny S.B., Ivanchenko S.A., Gryshyna I.S. The Increase of Treatment Efficiency of Bacterial Rhinosinusitis. Vestnik problem biologii i meditsiny = Bulletin of Problems Biology and Medicine. 2018:(2):138– 141. (In Russ.) doi: 10.29254/2077-4214-2018-2-144-138-141.

27. Goh Y.H., Goode R.L. Current Status of Topical Nasal Antimicrobial Agents. Laryngoscope. 2000;110(6):875–880. doi: 10.1097/00005537-200006000-00001.

28. Lee V.S., Davis G.E. Culture-Directed Topical Antibiotic Treatment for Chronic Rhinosinusitis. Am J Rhinol Allergy. 2016;30(6):414–417. doi: 10.2500/ajra.2016.30.4380.